Although the effects of nitroprusside (NP) on myocardial function have been studied extensively, the effects of this vasodilator on the pulmonary vasculature have received less attention. In closed-chest anesthetized dogs, we used indicator dilution measurements of pulmonary blood volume (PBV), along -with measurements of pulmonary artery (Ppa) and left atrial (Pla) pressures, to address this problem in three experimental protocols. In protocol I, NP at 10-30 ftg/kg per min in volumeexpanded dogs reduced Ppa by 20% and Pla by 44% but produced no consistent change in PBV. In protocol II, NP at 1.8-5.4 pg/kg per min accompanied by autologous blood transfusion, sufficient to return Pla to the control level, resulted in no change in Ppa, but an increase in PBV from 8.8 to 9.9 ml/ kg (P < 0.05). In protocol m, NP at 2-6 fig/kg per min was compared to decreased venous return produced by partial occlusion of the inferior vena cava (TVC). With IVC occlusion adjusted to yield Pla equal to that during NP infusion, there was no difference in Ppa, but PBV was greater during NP infusion (10.5 ml/kg), compared to IVC occlusion (7.6 ml/kg, P < 0.05). In some experiments NP produced an increase in PBV when Pla and Ppa were reduced. In protocols II and m, NP decreased pulmonary vascular resistance by 40-50% (P < 0.05) at equal levels of Ppa. We conclude that NP shifts the pressure-volume curve of the pulmonary vasculature so that greater volume and flow are accommodated at the same pressure and, under some conditions, may produce a paradoxical increase in PBV while reducing pulmonary vascular pressure. Ore Res 45: 1979 
SODIUM nitroprusside, in addition to being used for the treatment of hypertensive emergencies, more recently has been used for the treatment of congestive heart failure associated with myocardial infarction (Rowe and Henderson, 1974; Guiha et al., 1974) . Although the effects of nitroprusside on myocardial function and systemic hemodynamics have been thoroughly investigated (Rowe and Henderson, 1974; Guiha et al., 1974; Miller et al., 1976; Pagani et al., 1978) , the effect of nitroprusside on the pulmonary circulation, especially the pressurevolume characteristics of the pulmonary vasculature, has received less attention. Because the respiratory symptoms in congestive heart failure are related to changes in pulmonary blood volume (PBV) as well as pulmonary vascular pressure, we have studied the effect of nitroprusside on the relationship of PBV to pulmonary artery (Ppa) and left atrial (Pla) pressures. Previous reports indicate that nitroprusside causes reductions in PA and LA pressures and variable changes in cardiac output and pulmonary vascular resistance in man (Rowe and Henderson, 1974; Guiha et al., 1974) . Earlier investigations have shown that the administration of ganglionic blocking agents that produce similar changes in vascular pressures causes a reduction in PBV (Sarnoff and Berglund, 1952a) . In contrast, Tarazi et al. (1976) noted that the infusion of nitroprusside in hypertensive patients caused a fall in systemic blood pressure, Ppa, and pulmonary artery wedge pressure with no significant changes in "cardiopulmonary blood volume," suggesting that nitroprusside might have a vasodilator effect on the pulmonary vasclature. The three experimental approaches used in this study require some explanation. Any investigation into the effect of a vasodilator on the pressurevolume characteristics of the pulmonary circulation is complicated by two factors: first, the simultaneous effect of the agent on the volume and capacitance of the much larger systemic circulation; and second, the nonlinear pressure-volume relationship of the pulmonary vasculature (Sarnoff and Berglund, 1952b) . With a large increase in the volume of systemic capacitance vessels, both PBV and pulmonary vascular pressures may be reduced despite an increase in pulmonary vascular compliance. Because of the non-linear pressure-volume relationship, the ratio of PBV to pulmonary vascular pressure does not provide a valid measure of pulmonary vascular compliance. Instead, it is necessary to measure a change in pressure at constant volume or a change in volume at constant pressure. Accordingly, three approaches were used to examine the direct effect of nitroprusside on the pulmonary circulation. In protocol I, nitroprusside infusion in volume-expanded dogs produced decreases in pulmonary vascular pressures and variable changes in PBV, but no significant change in the average value. In protocol II, autologous blood transfusion was used to control pulmonary vascular pressure during nitro-prusside infusion. In protocol HI, nitroprusside infusion was compared to reductions in venous return accomplished by means of partial occlusion of the inferior vena cava (IVC). In protocol II and protocol III, the volume of blood transfused and the degree of FVC occlusion, respectively, were adjusted to allow detection of changes in PBV at the same level of pulmonary vascular pressure.
Methods
These studies were performed on 15-to 2O-kg, closed-chest, mongrel dogs anesthetized with pentobarbital (25 mgAg, iv, initial dose, followed by an infusion of 2 mg/kg per hour). The dogs were ventilated mechanically through a cuffed endotracheal tube with tidal volumes equal to 15 mlAg and hyperinflations every 7 minutes. They were paralyzed with gallamine triethiodide, 1 mg/kg, iv, 30 minutes prior to each set of measurements. The dogs were studied in the right lateral decubitus position.
Identical catheters (#7 Shirey, transvalvular retrograde catheters, USCI) were passed directly into the pulmonary artery (PA) and retrogradely into the left atrium (LA) for the measurement of pressures and injection of indicator. Right atrial (RA) pressure was measured with a balloon-tipped triplelumen catheter (#9 Dotter-Lukas cardiovascular catheter, USCI), which also was used to produce partial occlusion of the IVC. Pleural pressures were estimated with a 5-cm esophageal balloon placed in the lower esophagus in a position which yielded the lowest esophageal pressure. The aortic pressure transducers were calibrated in mm Hg, and PA, LA, RA, and esophageal pressure transducers were calibrated in cm H2O. All pressure transducers were leveled at the midthoracic level. Zone 2-3 and 3 blood flow conditions (West et al., 1964) were determined by measuring the vertical distance between the transducers and the top of the thorax.
PBV was determined by a double-injection (PA and LA), single-sample (aorta) method using indocyanine green dye. Injections were made with a pneumatic injector (Columbus Instruments) at a constant rate of 7 ml/sec. The concentration of green dye in aortic blood was measured using a flow-through cuvette densitometer (model 103 LR, Gilford Instruments). These data were converted to digital form with a 0.2-second sampling rate and processed in a digital computer (Hewlett-Packard, model 2100A). In all curves, at least 50% of the downslope could be approximated by a single exponential, with a correlation between time and the logarithm of indicator concentrations of at least 0.99. Mean transit time for each curve was calculated by adding the time interval between injector activation and indicator appearance to the ratio of moment to area for the curve. PBV, calculated from the product of cardiac output and the difference in mean transit times between PA and LA injections, was based on two pairs of indicator dilution curves resulting from alternate injections into the PA and LA.
The distending pressure in the pulmonary vasculature (Ppvd) was estimated as the average Ppa and Pla, i.e., Ppvd = (Ppa + Pla)/2 (Yu, 1969; Milnor et al., 1960) .
Each animal served as its own control in an individual experiment, and variability is expressed as standard error of the mean (SE). Student's t-test for paired data was used to determine the level of significance. A probability of less than 0.05 was considered significant.
Three types of experiments were conducted. After interventions, an interval of at least 20-30 minutes was allowed for vascular pressures to stabilize before making measurements of cardiac output and PBV.
Protocol I: Nitroprusside Infusion in Volume-Expanded Dogs
Four dogs were infused with normal saline until the initial LA pressure (7-14 cm H2O) had doubled. This required 2-3 liters of saline. After control measurements, nitroprusside was infused at a rate (10-30 jug/kg per min) which lowered LA pressure by 30-50%. Finally, nitroprusside was discontinued, and after 40 minutes, the measurements were repeated.
Protocol II: Nitroprusside Infusion Accompanied by Autologous Blood Transfusion
In six dogs, autologous blood transfusion was used to return LA pressure to the control level during nitroprusside infusion. Initially, these dogs were phlebotomized by a volume of blood equal to 25 ml/kg and infused with an equal volume of saline at least 2 hours before control measurements. The purpose of the phlebotomy was to obtain autologous blood for reinfusion later in the experiment. Subsequent to control measurements, nitroprusside infusion (1.8-5.4 jugAg per min) was started to lower the LA pressure by 5 cm of water. After pressures were stable, the autologous blood was reinfused over a 20-to 30-minute period in an amount sufficient to increase LA pressure to the control level. This required 70-85% of the initial phlebotomized volume of blood. Following this, nitroprusside was discontinued, and after 40 minutes, final measurements were obtained.
Protocol HI: Nitroprusside Infusion in Comparison to Decreased Venous Return
In four dogs, partial IVC occlusion was used to reduce venous return and produce reductions in LA pressure equal to those produced by nitroprusside infusion (1.8-6.0 /ig/kg per min). Two experiments were performed in the sequence: control, IVC occlusion recovery, nitroprusside infusion, recovery. The other two experiments reversed the sequence. By design, in all four experiments, LA pressures during IVC occlusion and during nitroprusside infusion were equal. In these experiments, the LA pressure was reduced by 40-100% of the initial control value.
Results
Protocol I: Nitroprusside Infusion in Volume-Expanded dogs.
In protocol I experiments, nitroprusside infusion reduced all vascular pressures, but only the changes in LA and systemic arterial pressures were significant (Table 1 ). There was no consistent change in PBV. Figure 1 shows the individual changes in the pulmonary vascular distending pressure and PBV. Despite the decrease in pressure in all four dogs, PBV increased in one experiment and was unchanged in the other two.
Protocol II: Nitroprusside Infusion Accompanied by Autologous Blood Transfusion
In protocol II experiments, in contrast to protocol I experiments, during the nitroprusside infusion, LA pressures were returned to the control level by autologous blood transfusion. The combination of nitroprusside infusion and autologous blood transfusion to control LA pressure resulted in a PA pressure equal to the control value, a PBV greater than the control value, and a pulmonary vascular resistance less than the control value (Table 1) . Figure 2 shows the individual changes in pulmonary vascular distending pressures and PBV. When nitroprusside infusion was discontinued, PBV increased further as the result of increases in pulmonary vascular pressures. In this type of experiment, the relationships between LA pressure and the vertical height of the lung indicated that zone 3 pulmonary blood flow conditions (West et al., 1964) existed in each experiment during control and nitroprusside infusion.
Protocol HI: Nitroprusside Infusion in Comparison to Decreased Venous Return
In protocol III experiments, the nitroprusside infusion rate and the degree of IVC occlusion were adjusted to decrease LA pressures to the same level x 10 3 X 10 3 X 10 3 * X 10 3 X 10 3
x 10 3 X 10 3 X 10 3 X lO 3 ! X 10 3 X 10 3 X 10 3
x 10 3 x 10 3 x 10 3 x 10" in each dog. This resulted in PA pressures which were equal during both nitroprusside infusion and IVC occlusion, but the PBV was greater and the pulmonary vascular resistance was less during nitroprusside infusion in comparison to IVC occlusion ( Table 1 ). The individual responses are shown in Figure 3 . In each dog, IVC occlusion reduced PBV. In all dogs, nitroprusside infusion was associated with a greater PBV at the same vascular pressure in comparison to IVC occlusion. In two of the four dogs, nitroprusside increased PBV in comparison control measurement, even though Ppa and Pla were reduced. In these experiments, the relationships between LA pressure and the vertical height of the lung indicated that zone 2-3 pulmonary blood flow conditions (West et aL, 1964) existed in each experiment during IVC occlusion and nitroprusside infusion.
The fact that interventions to control LA pressure in protocol II and protocol III experiments also resulted in PA pressures equal to the appropriate control values (Figs. 2 and 3) was unexpected. It indicates that the decrease in pulmonary vascular resistance was offset by a proportional increase in cardiac output. In designing the experiments, we anticipated that the decrease in pulmonary vascular resistance would be greater than the increase in cardiac output. This would have resulted in a lower PA pressure during nitroprusside infusion when LA pressures were controlled, or a higher LA pressure if PA pressure were controlled. Hence, we chose to control LA pressure so that interpretation of increases in PBV would not be obscured by an increase in LA pressure.
In each type of experiment, nitroprusside infusion increased heart rate and cardiac output and reduced systemic vascular resistances, but the magnitude of these changes was variable and did not achieve statistical significance in all experimental groups (Table 1 ).
Discussion
We have found that nitroprusside, in addition to reducing pulmonary vascular pressure through its actions on the systemic circulation, also produces a change in the pressure-volume characteristics of the pulmonary vascular bed, so that a larger volume of blood is accommodated at the same pulmonary vascular-distending pressure. Because of the curvilinear nature of the pressure-volume curve for the pulmonary vascular bed (Sarnoff and Berglund, 1952b) , it was not possible to determine the effect of nitroprusside when both pressure and volume changed in protocol I experiments. Although these experiments suggested that nitroprusside changes the pressure-volume characteristics of the pulmo- The effects of nitroprusside on PBV in protocol II experiments are illustrated. During the nitroprusside infusion, pulmonary vascular distending pressure (Ppvd) was held at control levels with autologous blood transfusion. PBV increased in all dogs despite minimal or no change in pulmonary vascular distending pressure. VOL. 45, No. 3, SEPTEMBER 1979 5.
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FIGURE 3 PBV and pulmonary vascular distending pressure (Ppvd) during IVC occlusion and nitroprusside infusion are compared in protocol III experiments. The broken lines with arrows indicate the direction of events-i.e., either nitroprusside infusion or IVC occlusion took place first in the experimental sequence. There were minimal differences in pulmonary vascular distending pressures between IVC occlusion and. nitroprusside infusion, but in each instance PBV was always greater during nitroprusside infusion.
nary vasculature, no statistical test could be applied to the data. Protocols II and III were designed to overcome this problem. In protocol II experiments, blood transfusions kept PA and LA pressures equal to the control values during nitroprusside infusion. In each experiment there was increased PBV during nitroprusside infusion. In protocol III experiments, the effects of nitroprusside on the systemic circulation were simulated by partial FVC occlusion. Although pulmonary vascular pressures were equal during IVC occlusion and nitroprusside infusion, PBV was greater during the nitroprusside infusion in each experiment. We have used the average of PA and LA pressure as a measure of pulmonary vascular distending pressure. It is known that the interstitial pressures surrounding the pulmonary blood vessels will contribute to the net transmural distending pressure; however, the magnitude of these pressures cannot be measured directly (Hughes, 1971) . In these experiments, we did use an esophageal balloon to estimate pleural pressure. Since we found no significant change in esophageal pressure in response to any of the interventions, it is unlikely that changes in interstitial pressure or lung volume could have produced an increase in the net transmural distending pressure of the pulmonary vasculature during nitroprusside infusion.
From the measurements we have made, we can only speculate on the mechanism(s) by which nitroprusside produces an increase in PBV. Since nitroprusside infusion produces an increase in cardiac output, it is possible that the increase in cardiac output might be responsible for the increased PBV. However, Permutt et al. (1969) showed that the factor limiting an increase or decrease in PBV is the inflow pressure, rather than the blood flow or the outflow pressure. In man, PBV also appears to be determined by pulmonary vascular pressure; but an indirect effect of stroke volume cannot be excluded (Forsberg, 1964; Dock et al., 1961; Roy et aL, 1965a) . Based on these observations, it is unlikely that increased cardiac output could be solely responsible for the increased PBV.
The practice of averaging PA and LA pressure, for the purpose of describing the pressure-volume characteristics of the pulmonary vasculature, assumes a uniform distribution of vascular resistance with respect to vascular compliance between the PA and LA. We cannot exclude the possibility that redistribution of resistance caused a greater portion of the vascular bed to be exposed to the inflow pressure. This would lead to an increase in PBV at constant pressure without real change in the elastic properties of any segment of the vascular bed. In general, however, the importance of the elastic properties of the pulmonary vascular bed in mediating physiological changes in PBV has been the subject of controversy. There is evidence that the recruitment of new vascular channels rather than distension of blood vessels may be the mechanism by which PBV increases with increases in pulmonary vascular pressure (Permutt et al., 1969) . If the process of recruitment is governed by smooth muscle tone which determines the critical opening pressure of some channels, nitroprusside, by reducing smooth muscle tone, could lower critical opening pressure and accomplish recruitment at constant vascular pressure in this fashion. The observation that the effect of nitroprusside was greater when part of the lung was under zone 2 and 3 conditions than when the entire lung was under zone 3 conditions might be taken as evidence in favor of recruitment, as opposed to changes in pulmonary vascular distensibility. Under zone 2 and 3 conditions, there is greater potential for the recruitment of vascular channels.
Although the response to nitroprusside is accompanied by evidence of increased activity of the sympathetic nervous system, it is unlikely that the changes in PBV were mediated by cardiovascular reflexes. The pulmonary circulation is endowed with j8-adrenergic receptors which can lead to vasodilation in response to isoproterenol (Schreiner et al., 1968) ; however, the primary effect of the natu-rally occurring mediators, epinephrine and norepinephrine, is an increase in pulmonary vascular tone (Roy et al., 1965a) . In protocol i n experiments, where the increase in PBV was greatest, the difference in heart rate between nitroprusside infusion and IVC occlusion was smaller than the difference observed between the heart rates associated with nitroprusside infusion and control conditions in protocol I or II experiments. This observation suggests that cardiovascular reflexes may oppose, rather than mediate, the pulmonary vascular response to nitroprusside.
When nitroprusside is used for the treatment of congestive heart failure associated with myocardial infarction (Rowe and Henderson, 1974; Guiha et al., 1974) , the desired effect includes increased cardiac output and reduced pulmonary vascular pressure. Although an increased PBV is not always associated with congestive heart failure, there is evidence of an alteration in the pressure-volume relationship of the pulmonary vasculature which implies an increase in pulmonary vascular tone (Borst et al., 1957; Feeley et al., 1963; Schreiner et al., 1971) . The effectiveness of treating this condition with upright position, phlebotomy, tourniquet, and morphine is believed to result from a reduction in PBV (Ebert and Stead, 1940; Kounty et al., 1942; Roy et al., 1965b) . Since nitroprusside appears to affect the pressure-volume characteristics of the pulmonary vasculature through its action as a smooth muscle relaxant, the exact response will depend upon the amount of tone in the pulmonary vasculature. In clinical states known to be associated with increased pulmonary vascular tone, there may be a paradoxical increase in PBV in the face of a reduction in pulmonary vascular pressures when nitroprusside is infused.
